ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for alerts 실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.

SYRS Syros Pharmaceuticals Inc

5.34
-0.37 (-6.48%)
19 6월(6) 2024 - 마감
15분 지연
기업명 주식 심볼 시장 주식 타입
Syros Pharmaceuticals Inc SYRS 나스닥 보통주
  가격 변동 가격 변동 % 주식 가격 최근 거래 시간
-0.37 -6.48% 5.34 13:00:01
개장가 저가 고가 종가 전일 종가
5.61 5.24 5.61 5.34 5.71
시세 정보 더보기 »

최근 뉴스

일자 시간 출처 제목
13/06/202420:00BWSyros to Host Webcast Event on Higher-Risk Myelodysplastic..
08/06/202405:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/06/202405:30EDGAR2Form 8-K - Current report
14/05/202420:30BWSyros Reports First Quarter 2024 Financial Results and..
14/05/202419:42EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/05/202422:00BWSyros to Participate in Upcoming Investor Conferences
07/05/202420:00BWSyros to Report First Quarter 2024 Financial Results on..
09/04/202420:00BWSyros Receives Fast Track Designation from the FDA for..
03/04/202405:30BWSyros Reports Inducement Grants Under Nasdaq Listing Rule..
27/03/202420:30BWSyros Reports Fourth Quarter and Full Year 2023 Financial..
27/03/202419:57IHMARKETNEWSU.S. Stock Index Futures Point to a Rebound, Oil See..
25/03/202420:00BWSyros Announces Completion of Enrollment of 190 Patients..
20/03/202420:00BWSyros to Report Fourth Quarter and Full Year 2023 Financial..
27/02/202421:00BWSyros to Participate in TD Cowen 44th Annual Health Care..
15/02/202410:56EDGAR2Form SC 13G - Statement of acquisition of beneficial..
14/02/202410:22EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/02/202409:02EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/02/202408:59EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
08/01/202421:06EDGAR2Form 8-K - Current report
08/01/202421:00BWSyros Highlights Anticipated 2024 Milestones to Deliver on..
03/01/202406:15EDGAR2Form SC 13G - Statement of acquisition of beneficial..
27/12/202307:19EDGAR2Form SC 13D/A - General statement of acquisition of..
20/12/202306:59EDGAR2Form 8-K - Current report
20/12/202306:53EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
19/12/202321:27BWSyros Announces Pricing of $45.0 million Underwritten..
15/12/202306:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/12/202306:12EDGAR2Form 144 - Report of proposed sale of securities
09/12/202306:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/12/202306:00EDGAR2Form 144 - Report of proposed sale of securities
06/12/202321:05EDGAR2Form 8-K - Current report
06/12/202321:00BWSyros Announces Encouraging Initial Data from Randomized..
06/12/202307:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/11/202321:30BWSyros to Participate in Upcoming Investor Conferences
14/11/202321:30BWSyros Reports Third Quarter 2023 Financial Results and..
14/11/202320:47EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202321:30BWSyros to Report Third Quarter 2023 Financial Results on..
03/11/202305:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/11/202305:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/11/202305:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/11/202305:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/10/202305:15EDGAR2Form SC 13D - General statement of acquisition of beneficial..
02/10/202321:49EDGAR2Form 8-K - Current report
02/10/202321:45BWSyros Announces Planned CEO Leadership Transition and..
08/09/202305:30BWSyros Reports Inducement Grants Under Nasdaq Listing Rule..
12/08/202305:30EDGAR2Form 8-K - Current report
08/08/202320:30BWSyros Reports Second Quarter 2023 Financial Results and..
08/08/202319:53EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
05/08/202305:30BWSyros Reports Inducement Grants Under Nasdaq Listing Rule..
03/08/202305:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/08/202320:30BWSyros to Report Second Quarter 2023 Financial Results on..